MX2021004365A - Conjugados de polinucleotido inmunomoduladores y metodos de uso. - Google Patents

Conjugados de polinucleotido inmunomoduladores y metodos de uso.

Info

Publication number
MX2021004365A
MX2021004365A MX2021004365A MX2021004365A MX2021004365A MX 2021004365 A MX2021004365 A MX 2021004365A MX 2021004365 A MX2021004365 A MX 2021004365A MX 2021004365 A MX2021004365 A MX 2021004365A MX 2021004365 A MX2021004365 A MX 2021004365A
Authority
MX
Mexico
Prior art keywords
methods
immunomodulating polynucleotide
cell
modulating
natural killer
Prior art date
Application number
MX2021004365A
Other languages
English (en)
Inventor
Jaume Pons
Bang Janet Sim
Tracy Chia- Chien Kuo
Curt W Bradshaw
Hong I Wan
Original Assignee
Tallac Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tallac Therapeutics Inc filed Critical Tallac Therapeutics Inc
Publication of MX2021004365A publication Critical patent/MX2021004365A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente se proporciona un conjugado para modular una célula asesina natural o una célula mieloide, que comprende una porción de direccionamiento y un polinucleótido inmunomodulador. También se proporciona en la presente una composición farmacéutica para modular una célula asesina natural o una célula mieloide, que comprende un conjugado que comprende una porción de direccionamiento y un polinucleótido inmunomodulador, y un excipiente farmacéuticamente aceptable. Adicionalmente, se proporcionan en la presente métodos para su uso para modular una célula asesina natural o una célula mieloide y para tratar una enfermedad proliferativa.
MX2021004365A 2018-10-17 2019-10-16 Conjugados de polinucleotido inmunomoduladores y metodos de uso. MX2021004365A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862747070P 2018-10-17 2018-10-17
US201862747611P 2018-10-18 2018-10-18
PCT/US2019/056619 WO2020081744A1 (en) 2018-10-17 2019-10-16 Immunomodulating polynucleotide conjugates and methods of use

Publications (1)

Publication Number Publication Date
MX2021004365A true MX2021004365A (es) 2021-07-06

Family

ID=70284225

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004365A MX2021004365A (es) 2018-10-17 2019-10-16 Conjugados de polinucleotido inmunomoduladores y metodos de uso.

Country Status (12)

Country Link
US (1) US20220096649A1 (es)
EP (1) EP3866858A4 (es)
JP (1) JP2022508825A (es)
KR (1) KR20210102204A (es)
CN (1) CN113660955A (es)
AU (1) AU2019360216A1 (es)
BR (1) BR112021007294A2 (es)
CA (1) CA3116880A1 (es)
IL (1) IL282282A (es)
MX (1) MX2021004365A (es)
SG (1) SG11202103805SA (es)
WO (1) WO2020081744A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115427458A (zh) 2020-02-28 2022-12-02 塔拉克治疗公司 转谷氨酰胺酶介导的缀合
EP4388103A1 (en) * 2021-08-20 2024-06-26 Tallac Therapeutics, Inc. Nectin-4 antibodies and conjugates
AU2022332287A1 (en) * 2021-08-25 2024-02-29 Tallac Therapeutics, Inc. Sirp-alpha antibodies and conjugates
WO2023081934A1 (en) * 2021-11-08 2023-05-11 The University Of Chicago Methods and compositions for pkc-delta inhibition and cancer immunotherapy
WO2023225577A1 (en) * 2022-05-18 2023-11-23 Tallac Therapeutics, Inc. Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3066105A4 (en) * 2013-11-06 2017-10-11 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups
US20170114341A1 (en) * 2014-06-06 2017-04-27 Solstice Biologics, Ltd. Polynucleotide constructs having bioreversible and non-bioreversible groups
US20180134802A1 (en) * 2016-01-08 2018-05-17 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same
US20210162064A1 (en) * 2016-02-19 2021-06-03 Genisphere Llc Nucleic Acid Carriers And Therapeutic Methods Of Use
JOP20190009A1 (ar) * 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها

Also Published As

Publication number Publication date
JP2022508825A (ja) 2022-01-19
CA3116880A1 (en) 2020-04-23
AU2019360216A1 (en) 2021-05-13
WO2020081744A1 (en) 2020-04-23
EP3866858A4 (en) 2022-10-26
US20220096649A1 (en) 2022-03-31
SG11202103805SA (en) 2021-05-28
KR20210102204A (ko) 2021-08-19
EP3866858A1 (en) 2021-08-25
IL282282A (en) 2021-05-31
BR112021007294A2 (pt) 2021-07-27
CN113660955A (zh) 2021-11-16

Similar Documents

Publication Publication Date Title
MX2021004365A (es) Conjugados de polinucleotido inmunomoduladores y metodos de uso.
EP4223316A3 (en) Improved antibody-oligonucleotide conjugate
JOP20220130A1 (ar) مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
MX2020012679A (es) Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
MX2020012997A (es) Conjugados de anticuerpo modulador de empalme-farmaco y metodos de uso.
PH12019502288A1 (en) Ask1 inhibitor compounds and uses thereof
WO2020236825A3 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12021550442A1 (en) Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
EP4324460A3 (en) Sodium bicarbonate for use in the treatment of gout and related disorders
PH12019501896A1 (en) Therapeutic dendrimers
MX2021002380A (es) Conjugados de isoquinolina-esteroide y usos de los mismos.
EA202191131A1 (ru) Конъюгаты антитело-лекарственное средство, содержащие производные эктеинасцидина
EP3804764A4 (en) TREATMENT OF HER2 MUTANT CANCER BY ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE
MX2021005878A (es) Modulador de empalme de herboxidieno de conjugados de anticuerpo-farmaco y metodos de uso.
PH12020552274A1 (en) Formulations of an axl/mer inhibitor
MX2023003448A (es) Composicion farmaceutica que comprende conjugado de anticuerpo-farmaco y uso de la misma.
MX2023005371A (es) Moduladores de receptor gamma activado por proliferador de peroxisoma (ppar gamma) y metodos de uso.
MX2021001832A (es) Conjugados para su uso en metodos de tratamiento del cancer.
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
MX2022001678A (es) Derivados amidas hibridas de anfotericina b.
MX2023012861A (es) Conjugado anticuerpo-farmaco dirigido a nectina-4 y metodo de preparacion del mismo y uso del mismo.